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http://dxBackground:Although systemic hypertension is closely associated with aortic aneurysm (AA) formation, there
are many patients with AA without hypertension. In these patients, an inflammation-mediated progression of
aneurysmal disease is likely responsible for AA growth and eventual rupture. Unfortunately, there remains
no reproducible and durable small animal model of aortic aneurysmal disease, the development of which would
enable the investigation of the pathophysiology of this vexing condition. The first aim was to establish a useful
wild-type mouse model of AAwith low mortality. The second aim was to use this model to assess the protective
effect of azelnidipine, a new calcium channel blocker, against the progression of the AA independent of its
antihypertensive effect.
Methods: Angiotensin II and b-aminopropionitrile (a lysyl oxidase inhibitor) were administrated subcutane-
ously in 7-week-old C57BL/6J mice using an osmotic minipump for 4 weeks to generate a wild-type mouse
model of AA. Concurrently, azelnidipine (a calcium channel blocker) or a placebo was administrated orally
for 4 weeks. Mice were humanely killed and assessed at the end of the 4 weeks of pharmacologic manipulation.
Results: The combined infusion of angiotensin II and b-aminopropionitrile induced degenerative aneurysm of
the thoracic and/or abdominal aorta (11/12; 92%). The majority of aneurysms were located in the distal aortic
arch and suprarenal abdominal aorta. Although there was no difference in systolic blood pressure between the
control and azelnidipine-treated groups, azelnidipine significantly reduced the incidence of AA (2/11; 18%).
Azelnidipine treatment reduced the pathologic findings normally associated with aneurysm formation within
the aortic wall. Azelnidipine also reduced the number of macrophage antigen-3 (MAC-3)–positive cells in
the periaortic adipose tissue and reduced the gene expression levels of tumor necrosis factor-alpha and matrix
metalloproteinase-2 and -9 within the aortic wall.
Conclusions: This study demonstrates that combined treatment with angiotensin II and b-aminopropionitrile
induces degenerative AAs in wild-type mice, and azelnidipine prevents aneurysm progression via its
anti-inflammatory effect. (J Thorac Cardiovasc Surg 2013;146:1501-8)The incidence of aortic aneurysmal disease is increasing, ow-
ing to anagedpopulationand improvedscreeningmethods.1-3
As less invasive methods of endovascular treatment of aortic
aneurysms (AAs) become more common and outcomes
improve, open surgery is no longer the only option for
patients, which allows treatment of aneurysmal disease in
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retard the growth of AAs. After identification of an
aortic aneurysmal lesion, physicians treat the patient
with antihypertensive medications and conduct serial
ultrasonographic examinations until the aneurysm grows
to a size at which intervention is indicated. Although it
has been demonstrated both clinically and experimentally
that systemic hypertension is closely associated with AA
formation, there are certainly many patients with AAs
who are normotensive.7-9 Therefore, the establishment of
an experimental model of AAs that is independent of
hypertension may provide insights into aneurysm formation
and propagation, which most importantly may lead to novel
targets of therapeutic intervention.10
The degeneration or disorganization of the elastic lamina
within the aortic wall that occurs with aging is closely asso-
ciated withAA progression.7-9,11,12 The extracellular matrix
of the aortic wall is predominantly composed of collagen
and elastin fibers, which are enzymatically cross-linked by
lysyl oxidase.13 Previous studies have demonstrated that
the activity of lysyl oxidase decreases with aging14,15
and that degeneration of elastic fibers is induced bydiovascular Surgery c Volume 146, Number 6 1501
Abbreviations and Acronyms
AA ¼ aortic aneurysm
BAPN ¼ b-aminopropionitrile
EVG ¼ elastica van Gieson
H&E ¼ hematoxylin and eosin
MMP ¼ matrix metalloproteinase
RT-PCR ¼ reverse-transcriptase polymerase chain
reaction
TNF-a ¼ tumor necrosis factor-alpha
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Sb-aminopropionitrile (BAPN), an inhibitorof lysyloxidase.16-18
Recently, amousemodel of thoracic and abdominalAAs has
been developed using the combination of angiotensin
II–induced hypertension and BAPN-induced elastic lamina
degeneration; however, the study was limited by a prohibi-
tively high mortality rate.16
Therefore, the first aim of this study is to establish a useful
wild-type mouse model of AAwith low mortality. The sec-
ond aim of this study is to assess the protective effect of
azelnidipine against the progression of AA independent of
its antihypertensive effect. Azelnidipine is a newly devel-
oped Ca2þ channel blocker and has been demonstrated to
have an anti-inflammatory effect independent of its antihy-
pertensive effect.19-22
METHODS
All animal experiments were conducted in accordance with the ‘‘Guide
for the Care and Use of Laboratory Animals’’ (National Institutes of Health
Publication No. 85-23, revised 1996). The Institutional Review Board at
Tokushima University approved all animal procedures.
Induction of AA and Azelnidipine Treatment
Seven-week-old C57BL/6J male mice (CLEA Japan, Inc, Tokyo, Japan)
were used. A placebo vehicle or a constant infusion of angiotensin II (1000
ng/kgbodyweight perminute) andBAPN(37.5mg/kg/d)were administrated
through a subcutaneously implanted osmotic pump (Alzet Osmotic Pumps;
Durect Corp, Cupertino, Calif) for 4 weeks.23,24 In our study, after
preliminary testing 3 different doses of BAPN (37.5, 75, and 150 mg/kg/d),
it was determined that 37.5 mg/kg led to rates of AA development of
90% to 100% with a survival of 80%. Therefore, we modified our
protocol and used BAPN at a dose of 37.5 mg/kg and the same dose of
1000 ng/kg/min angiotensin II that was used previously by Kanematsu
and associates.16 Mice were also administered concurrently either oral
azelnidipine (0.5 mg/kg/d25; Daiichi Sankyo Co, Ltd, Tokyo, Japan) or
a placebo for 4 weeks by gavage once a day (azelnidipine vs control).
Measurement of Blood Pressure
Systolic blood pressure was measured weekly using a tail-cuff method
(BP-98A, Softron, Japan) during the 4-week experimental period when
mice were undergoing pharmacologic administration and is presented
here as the average of 10 measurements.23
Tissue Harvesting and Macroanalyzing
Animalswere housed in a pathogen–free facility under climate-controlled
conditions with a 12-hour light/12-hour dark cycle and were provided with
standard diet chow (Oriental Yeast Co, Tokyo Japan) and water ad libitum.1502 The Journal of Thoracic and Cardiovascular SurAt the end of the 4-week drug infusion period, these mice were perfused
with cold phosphate-buffered saline (20 mL) under physiologic pressure,
and then the aorta between the heart and the aortic bifurcation and periaortic
fat tissue were harvested and used for tissue analysis and quantitative
reverse-transcriptase polymerase chain reaction (RT-PCR) analysis.
AAs were defined morphologically as a localized dilation of the aorta
with amaximal outer diameter larger than 50% of its adjacent intact portion
of the aorta, which are the same criteria used for defining human AAs.16
Images were analyzed using cellSens software (version 1.41; Olympus
Corporation, Tokyo, Japan) to measure the outer diameter of the aorta.
Histologic and Immunohistochemical Examinations
The harvested tissues were fixed in 4% paraformaldehyde and then em-
bedded in paraffin. Serial cross sections (5-mm thick) from both the tho-
racic and abdominal aortas were mounted on microscope slides and
examined histologically and immunohistochemically. The sections were
stained with hematoxylin and eosin (H&E) and elastica van Gieson (EVG).
Mac-3 (purified rat anti-mouse Mac-3 antibody; 550292; BD Pharmin-
gen, BD Biosciences, San Jose, Calif) immunohistochemical staining was
performed to identify macrophages in the aortic wall and perivascular ad-
ipose tissue. Antibody distribution was visualized using the avidin-biotin
complex technique and Vector Red substrate (Vector Laboratories, Inc,
Burlingame, Calif).
Quantitative RT-PCR by SYBR Green Detection
Method
The harvested tissues were stored immediately using RNAlater (Life
Technologies Corporation, Carlsbad, Calif). Total RNA was isolated
from the aortic tissue using TRIzol (Life Technologies Corporation) in ac-
cordancewith the manufacturer’s instructions. Tumor necrosis factor-alpha
(TNF-a; an inflammatory cytokine), matrix metalloproteinases (MMP-2
and MMP-9; regulating factors involved in degeneration of the aortic
wall), and SIRT-1 (an anti-aging molecule)26 mRNA expression levels
were determined by RT-PCR analysis (StepOne Real-Time PCR System;
Life Technologies Corporation). b-Actin was used as the housekeeping
gene. SYBR green was used to detect b-actin. Results were expressed as
arbitrary units in comparison with the mRNA expression level of b-actin.
Primer Sequences
The primer sequences were as follows: mouse TNF-a (sense 50-CCA
GACCCTCACACTCAGATC-30 and antisense 50-CACTTGGTGGTTTG
CTACGAC-30), mouse MMP-2 (sense 50-GATAACCTGGATGCCGTCG
TG-30 and antisense 50-CTTCACGCTCTTGAGACTTTGGTTC-30), mouse
MMP-9 (sense 50-GCCCTGGAACTCACACGACA-30 and antisense
50-TTGGAAACTCACACGCCAGAAG-30), and mouse SIRT-1 (sense
50-TGCAGACGTGGTAATGTCCAAAC-30 and antisense 50-ACATCTT
GGCAGTATTTGTGGTGAA -30).
As a housekeeping gene, b-actin was amplified with the following
primer set: sense 50-CATCCGTAAAGACCTCTATGCCAAC-30 and anti-
sense 50-ATGGAGCCACCGATCCACA -30.
Statistical Analyses
Data are presented as mean  standard error. To analyze variations be-
tween groups, we used the nonparametric Mann-Whitney test for paired
data. One-way analysis of variance with the post hoc (Newman-Keuls)
test was used to compare variations within groups.
RESULTS
Combined Infusion of Angiotensin II and BAPN
Induced Hypertension and AA Formation
The systolic blood pressurewas higher after infusion than
before infusion. Administration of azelnidipine had nogery c December 2013
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FIGURE 1. Blood pressure measurements. A, Changes over time in systolic blood pressure during the infusion of angiotensin II and BAPN. There is no
significant difference between groups (n¼ 12 in control group, n¼ 11 in azelnidipine group). B, Maximum blood pressure of each mouse after 4 weeks of
combination infusion therapy (n ¼ 12 in control group; n ¼ 11 in azelnidipine group). BAPN, b-Aminopropionitrile.
Kurobe et al Evolving Technology/Basic Sciencestatistically significant effect on either mean systolic or
maximum systolic blood pressure between the 2 groups
(Figure 1, A and B).
Among the mice that received the combined infusion of
angiotensin II and BAPN and were not treated with azelni-
dipine, 12 of 13 survived until the end of the pump infusion,
that is, 4 weeks, with 1 mouse dying prematurely owing to
dissecting AA. Of the surviving mice in this group, 91%
(11/12) had AA develop (Figure 2, A and B). Regarding
the type of AA that developed, 50% (6/12) had thoracic
AA (Figure 2, C) and 67% (8/12) had abdominal AA
(Figure 2, D). Three of the 12 (25%) surviving mice had
both thoracic and abdominal AAs.E
T
/B
SAzelnidipine Reduced the Incidence of AAFormation
Azelnidipine treatment in mice receiving the combined
infusion of angiotensin II and BAPN significantly reduced
the incidence of AA in all aortic regions compared with
vehicle treatment (azelnidipine vs vehicle; 18% vs 91%;
P ¼ .004) (Figure 2, B). The incidences of thoracic and ab-
dominal AAs was decreased by azelnidipine treatment from
50% (6/12) to 0% (0/11) (P¼ .02) and from 67% (8/12) to
18% (2/11) (P ¼ .04), respectively (Figure 2, C and D).Azelnidipine Reduced Degenerative Lesions in the
Aortic Wall
Histologic findings of H&E staining demonstrated that
combination infusion of angiotensin II and BAPN resulted
in mononuclear cell infiltration of the adventitia and media
and also in adventitial thickening of the aortic wall com-
pared with normal mice (Figure 3, A). Treatment of mice
with azelnidipine concurrently with combination infusion
attenuated these findings.The Journal of Thoracic and CarEVG staining showed that combination infusion of an-
giotensin II and BAPN accelerated degeneration and de-
struction of elastic layers and adventitial thickening of the
aortic wall (Figure 3, B). Azelnidipine rescued the mouse
aortas by preventing degenerative lesions within the elastic
layer, resulting in the aortic wall resembling that of normal
tissue (Figure 3, B).Macrophage Infiltration was Inhibited by
Azelnidipine Administration
Mac-3 immunohistochemical staining was performed to
analyze macrophage distribution within the aortic wall
and in periaortic fat (Figure 4, A). In the aortic wall of
mice with the combination-infusion–induced AAs, numer-
ous macrophages were observed in the adventitia and me-
dia. The number of macrophages in the arterial wall and
perivascular fat tissue was significantly decreased in mice
treated concurrently with azelnidipine (Figure 4, B).Azelnidipine Inhibited TNF-a and MMP-2, -9 Gene
Expression in Aortic Wall
The gene expression levels of TNF-a, an inflammatory
cytokine, and MMP-2 and MMP-9 in the arterial wall tissue
were evaluated by RT-PCR analysis. These gene expression
levels were increased by the combined infusion of angioten-
sin II and BAPN. Azelnidipine treatment attenuated this
finding and was found to be of statistical significance for
TNF-a, MMP-2, and MMP-9 (Figure 5, A, B, and C).Azelnidipine Increased Vascular SIRT-1 Gene
Expression Level in AAWall
The vascular SIRT-1 (an antiaging molecule) gene ex-
pression level in the aortic wall with aneurysm was notdiovascular Surgery c Volume 146, Number 6 1503
FIGURE 2. Morphologic changes of aorta after combination infusion with angiotensin II and BAPN. A, Representative images of aortic aneurysm.
Thoracic aortic aneurysm in upper panel. Abdominal aortic aneurysm in lower panel. BAPN, b-Aminopropionitrile; TAA, thoracic aortic aneurysm; AAA,
abdominal aortic aneurysm; BT, brachiocephalic trunk;CA, carotid artery; SA, subclavian artery; RA, renal artery; Ao, aorta; Lt, left; Rt, right. B to D, Aortic
ratio in each mouse. B, All aortic lesions. C, Thoracic aortic lesions. D, Abdominal aortic lesions. (n ¼ 12 in control group, n ¼ 11 in azelnidipine group.)
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BAPN. However, azelnidipine treatment significantly in-
creased the gene expression level of SIRT-1 in the AA
wall (Figure 5, D).
DISCUSSION
Aortic aneurysmal disease is an atherosclerotic disease
that affects elderly persons and is more common in
men than in women.27,28 Despite the increased rate of
diagnosis of this disease in recent years,1 many patients
do not fulfill the criteria for surgical treatment and are
therefore managed by medical treatment and serial com-
puted tomographic and ultrasound examinations. Unfortu-
nately, few medications have been demonstrated to inhibit
the progression of aortic aneurysmal disease besides anti-
hypertensives. A significant obstacle to drug development1504 The Journal of Thoracic and Cardiovascular Surfor this disease is the lack of a reliable and reproducible
animal model. The aims of this study, therefore, are two-
fold: to establish a small animal model of aortic aneurys-
mal disease without genetic modification and to evaluate
a novel pharmacologic agent for the treatment of this
entity.
Kanematsu and associates16 demonstrated that combi-
nation of angiotensin II–induced hypertension and lysyl
oxidase inhibition with BAPN induces AA formation in
C57BL/6J mice. However, this study was limited by
a prohibitively high mortality rate during the experimen-
tal period, which may have been related to high levels
of BAPN that led to rapid degeneration of the aortic
wall. Therefore, we modified our protocol after prelim-
inary BAPN-dose testing and used BAPN at a dose of
37.5 mg/kg and the same dose of 1000 ng/kg/mingery c December 2013
FIGURE 3. Histologic analysis of aorta. A, Hematoxylin and eosin (H&E) staining of aorta. LPF, Low-power field (bar shows length in 500 mm); HPF,
high-power field (bar shows 100 mm of length). B, Elastica van Gieson (EVG) staining of aorta (bar shows 100 mm).
Kurobe et al Evolving Technology/Basic Scienceangiotensin II that was used previously by Kanematsu
and colleagues,16 and we administered these drugs by
infusion via a subcutaneous osmotic pump. Thus weFIGURE 4. Mac-3 immunohistochemical staining of aorta. A, Representativ
length). B, The number of Mac-3-positive cells in aortic lesions was counted i
and BAPN), azelnidipine group (treated with the combination infusion plus azel
wall; right panel: periaortic adipose tissue; n ¼ 7 in each group. BAPN, b-Ami
The Journal of Thoracic and Carobtained rates of AA development of 90% to 100%
with a survival of 80%. Our experimental period was 4
weeks, which was shorter than theirs, and our study aftere images of Mac-3 immunohistochemical staining (bar shows 50 mm of
n the control group (treated with a combination infusion of angiotensin II
nidipine administration), and normal group (nontreated). Left panel: aortic
nopropionitrile.
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FIGURE 5. Gene expression levels of TNF-a,MMP-2,MMP-9, and SIRT-1 in aortic wall. Real-time PCR analyses of (A) TNF-a, (B)MMP-2, (C)MMP-9,
and (D) SIRT-1 were performed in mice treated with combination infusion of angiotensin II and BAPN only (control group), mice administered azelnidipine
and combination infusion (azelnidipine group), andmice treatedwith placebovehicle (normal group).Values are expressed asmean standard error (n¼ 7 in
each group). TNF-a, Tumor necrosis factor-alpha; MMP, matrix metalloproteinase; RT-PCR, reverse-transcriptase polymerase chain reaction; BAPN,
b-aminopropionitrile.
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91% (12/13). Additionally, 11 (91%) of the 12 mice
that survived had AAs at 4 weeks. One of the aims of
this study was to establish a unique animal model of de-
generative AA in C57BL/6J mice without genetic mod-
ification with high reproducibility and low mortality
rate. Herein, we have developed a model that achieves
those goals and enables future in vivo study of the path-
ogenesis of aortic aneurysmal disease and evaluation of
pharmacologic interventions.
The pathophysiology and molecular pathway by which
AAs develop, progress, and eventually rupture in humans1506 The Journal of Thoracic and Cardiovascular Surremain unclear. The aortic wall consists of 3 layers: the in-
tima, media, and adventitia. The extracellular matrix is
composed primarily of elastin and collagen, both of which
are important components of the media and adventitia.
Elastin is found predominantly in the medial layer,
whereas collagen is concentrated in the adventitia. It has
previously been demonstrated that elastin degradation
in the adventitia may be the most important factor in
the rupture of AAs.29,30 Degeneration of aortic wall
layers by inflammatory stimuli and/or aging results in the
progression of aortic aneurysmal disease in humans.29,30
Although a previous study showed a correlation betweengery c December 2013
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AA,16 the results presented here reveal a similar patho-
physiology in degenerative AA formation.
Calcium antagonists are often used clinically for
hypertensive patients with AAs. Azelnidipine, a calcium
antagonist, was previously reported to have some anti-
inflammatory effect in vitro,19,20,22 but there are few
studies that demonstrate its effects on AA progression
in vivo. In the present study, azelnidipine drastically
inhibited the progression of drug-induced mouse degener-
ative AA independent of its antihypertensive effect. We
found that azelnidipine administration significantly in-
hibited macrophage infiltration into the aortic wall and
the periaortic adipose tissue and also decreased the gene
expression levels of inflammatory cytokines within the
aortic wall. Macrophages produce inflammatory cytokines
such as monocyte chemotactic protein 1, interleukin 6,
TNF-a, and MMPs,31,32 and in perivascular adipose
tissues, they have been shown to be strongly associated
with atherosclerosis progression. Inasmuch as AA
disease is considered in part a chronic inflammatory
disease, it is clear that macrophages play a crucial role
in the progression of aortic remodeling in the presence
of aneurysmal dilatation.33,34 Our results suggest that
azelnidipine has the anti-inflammatory effect that alters
aortic remodeling, which is consistent with previous stud-
ies demonstrating the anti-inflammatory effect of azelnidi-
pine in vitro.19-22
Although azelnidipine had the anti-inflammatory effect
in our model as evidenced by the decreased expression
levels of TNF-a, MMP-2, and MMP-9, it conversely en-
hanced gene expression level of vascular SIRT-1. Vascular
SIRT-1 possesses cardiovascular protective properties26
and improves the function of vascular smooth muscle and
vascular endothelial cells.35,36 Schug and associates37 dem-
onstrated that myeloid deletion of SIRT-1 induces inflam-
matory signaling in vivo, and SIRT-1 exerts biological
actions as an anti-inflammatory molecule. Our data suggest
that the anti-inflammatory actions of azelnidipine may be
partly mediated by regulation of SIRT-1 expression in the
aortic wall. Importantly, the role of SIRT-1 needs further
clarification in this model, inasmuch as its mechanism
and its role independent of BAPN/angiotensin administra-
tion in mice treated with azelnidipine alone are currently
unknown.
In conclusion, the combination of hypertension and
BAPN-induced degeneration of the elastic lamina can
lead to degenerative AAs in a mouse model with high repro-
ducibility and low mortality rate. Azelnidipine suppresses
the formation of aortic aneurysmal disease via its anti-
inflammatory effect within the aortic wall and periaortic tis-
sue. These findings suggest that azelnidipine may be useful
as a novel pharmacologic agent to prevent the progression
of AAs.The Journal of Thoracic and CarWe are grateful to Mayuko Higashida MS (The University of
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